AT
BMRN icon

Arden Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arden Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,814
Closed -$337K – 282
2021
Q4 		$337K Sell
3,814
-49
-1% -$4.04K 0.06% 244
2021
Q3 		$299K Sell
3,863
-160
-4% -$12.6K 0.05% 248
2021
Q2 		$335K Sell
4,023
-322
-7% -$25.5K 0.06% 239
2021
Q1 		$328K Sell
4,345
-745
-15% -$60.9K 0.06% 249
2020
Q4 		$446K Sell
5,090
-320
-6% -$25.4K 0.07% 209
2020
Q3 		$412K Sell
5,410
-1,545
-22% -$156K 0.07% 211
2020
Q2 		$857K Sell
6,955
-1,669
-19% -$166K 0.16% 126
2020
Q1 		$729K Buy
8,624
+1,798
+26% +$155K 0.15% 128
2019
Q4 		$577K Sell
6,826
-454
-6% -$34.3K 0.09% 203
2019
Q3 		$491K Buy
7,280
+309
+4% +$23.8K 0.08% 218
2019
Q2 		$597K Buy
6,971
+663
+11% +$56.7K 0.1% 194
2019
Q1 		$561K Buy
6,308
+35
+0.6% +$3.24K 0.09% 213
2018
Q4 		$534K Buy
6,273
+587
+10% +$55.8K 0.1% 194
2018
Q3 		$551K Buy
5,686
+79
+1% +$7.89K 0.09% 207
2018
Q2 		$528K Buy
+5,607
New +$491K 0.08% 205

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Arden Trust's BMRN Position: Q1 2022 in Review

Arden Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 3,814 shares — an estimated $337K sold.

Arden Trust first reported a position in BMRN in Q2 2018 and held it in 15 quarters. The position peaked at $857K in Q2 2020. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Arden Trust reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Arden Trust sold 3,814 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $337K.
  • Arden Trust first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 15 quarters.
  • Arden Trust's BioMarin Pharmaceuticals position peaked at $857K in Q2 2020.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Arden Trust's 13F filing for Q1 2022, filed 11 Apr 2022.